Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations, SOR/2022-18
Section 22
Additional information prior to clinical trial
Cite as Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations, SOR/2022-18, s. 22 · current to July 24, 2025 · regulation last amended February 27, 2022
Statute Watch
Get an alert when a bill in Parliament would change this section, and every time it moves.
The text
A holder of a COVID-19 drug authorization must not import or sell a COVID-19 drug for which the authorization has been issued or conduct a clinical trial in respect of such a drug unless the holder has
(a) for each clinical trial site, obtained the approval of a research ethics board in respect of the protocol referred to in paragraph 20(2)(a) and the informed consent form that contains the statement referred to in paragraph 20(2)(b); and
(b) submitted to the Minister the information and material referred to in subparagraphs 20(2)(c)(ix) and (x) and paragraphs 20(2)(d) and (n), if it was not submitted at the time of submitting the application.
Read the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations on the Justice Laws Website ↗
Made under Food and Drugs Act, R.S.C. 1985, c. F-27; Patent Act, R.S.C. 1985, c. P-4.
Bills in Parliament that would change this section 0
No bill we hold would amend or repeal this section.